MEMERS AIVA A1: A New Generation of E-cigarette Technology

Feb.18.2025
MEMERS AIVA A1: A New Generation of E-cigarette Technology
MEMERS VAPE, a brand under Shenzhen Sikary Technology, introduces the new MEMERS AIVA A1 e-cigarette with innovative features.

Special statement:

This article is for internal industry communication only and does not make any recommendations for brands or products.

The images presented in this article are intended solely for factual description and are not to be used as advertisements for any products.

Minors are prohibited from accessing this article.


Shenzhen Sikary Technology Co., Ltd.'s e-cigarette brand MEMERS VAPE recently showcased a new open-pod e-cigarette, the MEMERS AIVA A1, on its official website. The product features a curved screen that can display functions such as charging countdown and stopwatch.

 

Specifically, the main product information for MEMERS AIVA A1 is as shown in the following table:

 

MEMERS AIVA A1: A New Generation of E-cigarette Technology
MEMERS AIVA A1 Parameters | Schematic: 2FIRSTS

 

In terms of product features, the MEMERS AIVA A1 has a side screen that includes functions such as charging countdown and stopwatch. Additionally, the AIVA A1 also comes equipped with multifunctional LED lights that support high beam, low beam, strobe, and SOS modes.

 

MEMERS AIVA A1: A New Generation of E-cigarette Technology
MERMERS AIVA A1 | Image source: MEMERS VAPE

 

AIVA A1 is equipped with an open pod system, with a pod capacity of 2ml, offering a total of 15 different product flavors.

 

MEMERS AIVA A1: A New Generation of E-cigarette Technology
MEMERS AIVA A1 | Image source: MEMERS VAPE

 

On the manufacturer's side, the MEMERS AIVA A1 is introduced by the e-cigarette brand MEMERS VAPE under Shenzhen Sikary Technology Co., Ltd. It is another open-pod e-cigarette product released by MEMERS VAPE following the Dr. AIR series.

 

MEMERS AIVA A1: A New Generation of E-cigarette Technology
MEMERS AIVA A1 product packaging | Image source: e-cigarette-forum

 

Previously, the brand has launched various products including the WuKong series (including 2+10, disposable hookahs, and ice & nicotine control products) and the refillable oil injection e-cigarette MEMERS Dr. AIR series. (Related reading: "Products | Sikary's MEMERS VAPE launches WuKong series: covering 2+10, disposable hookahs, and ice & nicotine control products", "Products | Comparison of refillable oil injection e-cigarettes from Sikary, VOZOL, GEEKVAPE all equipped with high-definition display screens")

MEMERS AIVA A1: A New Generation of E-cigarette Technology
WuKong" series products | Image source: MEMERS VAPE

 


The "2FIRSTS" product section is dedicated to providing readers with the latest information on new products in the tobacco industry. In order to gather and share first-hand information from the industry, "2FIRSTS" welcomes readers to submit articles and share the latest products in the e-cigarette field.

 

If you have any unique insights or information, feel free to contact us at info@2firsts.com or connect with 2Firsts CEO Alan Zhao on LinkedIn.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Product | HQD SiSA 80K Enters the U.S. Market With a Hookah-Inspired Approach to the High-Capacity Disposable Segment
Product | HQD SiSA 80K Enters the U.S. Market With a Hookah-Inspired Approach to the High-Capacity Disposable Segment
The HQD SiSA 80K Hookah Disposable Vape has appeared across U.S. and cross-border online retail channels. The device comes prefilled with 28ml of e-liquid, uses a 5% nicotine salt configuration and carries a brand claim of up to 80,000 puffs. Beyond puff count, the product differentiates itself through hookah-inspired features including adjustable airflow, a flowing-water sound effect and flavor options associated with traditional hookah consumption.
Aug.18
Scottish Vape Display Rules Could Cost Businesses £61 Million, Affecting More Than 11,000 Retail Outlets
Scottish Vape Display Rules Could Cost Businesses £61 Million, Affecting More Than 11,000 Retail Outlets
A Scottish government impact assessment estimates that proposed vape display and packaging rules could create up to £61 million ($82 million) in compliance costs for businesses, affecting more than 11,000 retail outlets. The estimated costs are mainly linked to inventory adjustments, retail storage changes and the resources required for businesses to understand and implement the new requirements. The measures form part of the UK’s broader efforts to tighten vape regulation, particularly around product displays, packaging and sales practices.
Aug.10
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09